In contrast, VISTA has a good prognosis in malignant pleural mesothelioma and breast cancer, specifically in triple-negative patients, cervical cancer, and endometrial cancer, with better overall survival in patients with higher VISTA expression. This evidence concerns the gene VSIR and cervical carcinoma.